• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

GLOMERULAR FILTRATION RATE

Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

June 19, 2020COVID-19, Vizit Graphs
Mechanisms by which Eculizumab (Soliris) may benefit COVID-19 patients with respiratory distress syndrome

Eculizumab is a biologic therapy, a complement C5 inhibitor, and has recently shown promise in COVID-19. The graph provides an important step towards elucidating the MoA of this drug in COVID-19. Explore the live graph.

Vizit Graphs Tag Cloud

RHEUMATOID ARTHRITIS AGING COVID-19 TNF APOPTOTIC PROCESS CASP3 COGNITION HELICOBACTER PYLORI ESCHERICHIA COLI IL2 LACTATE DEHYDROGENASE STAPHYLOCOCCUS AUREUS ALBUMIN INFLAMMATION ACE IL6 MYALGIA PD-1 PARKINSON DISEASE IFNG CELL DIFFERENTIATION CANCER ALZHEIMER'S DISEASE IL10 RAS TMPRSS2 CANDIDA ALBICANS ANGIOTENSIN II PSEUDOMONAS AERUGINOSA SARS-COV-2 METFORMIN INSULIN NEUTROPHILS LISTERIA MONOCYTOGENES CELL PROLIFERATION AUTOPHAGY INFLAMMATORY RESPONSE IMMUNITY INTERFERON IMMUNE RESPONSE COAGULATION ACE2 NFKB1 IL1B CD4

© 2021 Biovista Vizit All Rights Reserved.